Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data

Table 1

Association of CPEB3 expression and clinicopathological features in melanoma.

Characters	Level	Low expression of CPEB3, (%)	High expression of CPEB3, (%)
		234	234
OS event (%)	Alive	118 (51.3)	128 (55.4)	0.429
	Dead	112 (48.7)	103 (44.6)
T stage (%)	T0	12 (6.0)	11 (6.0)	<0.001
	T1	18 (9.0)	23 (12.5)
	T2	31 (15.5)	47 (25.5)
	T3	39 (19.5)	51 (27.7)
	T4	100 (50.0)	52 (28.3)
N stage (%)	N0	118 (56.5)	116 (57.4)	0.235
	N1	35 (16.7)	39 (19.3)
	N2	22 (10.5)	27 (13.4)
	N3	34 (16.3)	20 (9.9)
M stage (%)	M0	212 (94.6)	204 (94.4)	1.000
	M1	12 (5.4)	12 (5.6)
Clinical stage (%)	Stage 0	4 (1.9)	3 (1.5)	0.418
	Stage I	32 (15.0)	44 (21.7)
	Stage II	78 (36.6)	62 (30.5)
	Stage III	88 (41.3)	82 (40.4)
	Stage IV	11 (5.2)	12 (5.9)
Melanoma Clark level (%)	I	4 (2.5)	2 (1.3)	0.017
	II	7 (4.3)	11 (7.0)
	III	29 (18.0)	47 (29.7)
	IV	87 (54.0)	81 (51.3)
	V	34 (21.1)	17 (10.8)
Tumor status (%)	Tumor free	102 (44.3)	112 (48.7)	0.400
	With tumor	128 (55.7)	118 (51.3)
Gender (%)	Female	92 (39.3)	87 (37.2)	0.704
	Male	142 (60.7)	147 (62.8)
Age (median [IQR])		58.0 [49.0, 71.0]	58.0 [46.0, 71.0]	0.329
Height (median [IQR])		170.0 [164.0, 176.0]	172.0 [162.5, 179.5]	0.304
Weight (median [IQR])		79.0 [67.0, 87.5]	84.0 [70.0, 96.8]	0.012
BMI (median [IQR])		26.0 [23.3, 30.1]	27.5 [24.2, 33.2]	0.026
Tumor tissue site (%)	Extremities	93 (43.5)	102 (50.5)	0.143
	Trunk	95 (44.4)	76 (37.6)
	Head and neck	22 (10.3)	15 (7.4)
	Other specify	4 (1.9)	9 (4.5)
Ulceration (%)	No	65 (40.6)	80 (53.0)	0.039
	Yes	95 (59.4)	71 (47.0)

IQR: interquartile range. Statistically significant.